Synairgen plc (LON:SNG – Get Free Report)’s share price hit a new 52-week low on Friday . The company traded as low as GBX 2 ($0.02) and last traded at GBX 2 ($0.02), with a volume of 4307056 shares changing hands. The stock had previously closed at GBX 3.75 ($0.05).
Synairgen Stock Performance
The stock has a market cap of £4.03 million, a PE ratio of -66.67 and a beta of -2.23. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35. The stock has a 50-day simple moving average of GBX 4.50 and a 200-day simple moving average of GBX 4.46.
Synairgen Company Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Read More
- Five stocks we like better than Synairgen
- NYSE Stocks Give Investors a Variety of Quality Options
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- How Investors Can Find the Best Cheap Dividend Stocks
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
